




PSYCHEDELIC  
STOCK WATCH



# INVESTING

## In Early Medicinal Psychedelics

**FDA Officially Declares Psychedelics  
“Breakthrough Therapy”**

COMING IN 2020:

LAUNCH OF A \$300 BILLION+ BIOTECH REVOLUTION

# Investing Early in Medicinal Psychedelics

*FDA Officially Declares Psychedelics “Breakthrough Therapy”*

COMING IN 2020: LAUNCH OF A \$300 BILLION+ BIOTECH REVOLUTION... AND SAVVY INVESTORS WHO STEP UP NOW AND GET IN EARLY STAND TO MAKE A FORTUNE AS IT ALL PLAYS OUT!



**Breakthrough Therapy** = a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s) (US FDA)

Within the next three months, an event will take place that will propel one of the most sweeping changes the entire history of the healthcare industry.

It will come as the culmination of years of research along with a major capital market catalyst. And it will bring about some of the most disruptive and potentially life-changing treatments ever developed to conquer some of healthcare’s most problematic and, heretofore, hopeless conditions.

I am talking, here, about medicinal psychedelics going mainstream.

And the potential is astonishing.

The remarkable way these medications work... the years of intense tech industry research that has gone into bringing them to the market... and so very much more (much of it behind the scenes and under the radar) is now, at last, coming together to develop long-elusive treatments for:

- Deadly addictions,
- Debilitating depression,
- PTSD, and
- Other mental health conditions once thought all but incurable.

Today, it costs hundreds of billions of dollars to administer the current marginally effective treatments for these and other devastating mental illnesses.

But, all of that is soon about to change.

And savvy investors who step up now and get in early stand to make a fortune as it all plays out.

The fact is, everything is coming together at once for the medicinal psychedelics.

The capital marketplace has already started really heating up for the remainder of 2020.

As PharmaManufacturing magazine reports, “Psychedelics could tap into a large population of patients starved for new treatments. And for companies ready to jump on this colorful new bandwagon, the payout is expected to be huge.”

In short, the biggest is yet to come.

**And here is why -- and how -- now is the time for you to get in early... and cash out big.**

*“Psychedelic drugs may revolutionize mental health care.”*

**FORTUNE**

# 2020: Prime Time For Psychedelics

Let's face it, psychedelics don't have the best historical reputation.

Despite some advocates for their use like Apple guru Steve Jobs, who described using them as a "profound experience," the stereotypical user is a 60s hippie with limited energy, low motivation, sitting around listening to "Lucy in the Sky With Diamonds."

That, however, is recreational users – from a bygone day.

Today's world of serious medicinal psychedelics is a much different story altogether.

It's not in the sky. It's down to earth. And more importantly, it is already changing – and saving – lives.

Consider a recent article from the prestigious Wall Street Journal – the investors paper of record.

It reported that this new class of psychedelic-based drugs "can help alleviate depression, anxiety and addiction."

[Fortune magazine](#) – another seminal source for investors looking to maximize their returns – declared, "Psychedelic drugs may revolutionize mental health care." - Fortune

And [NBC News recently proclaimed](#), "Therapeutic 'trips'

*"Recent studies are finding that drugs such as LSD and psilocybin can help to alleviate depression, anxiety and addiction."*

THE WALL STREET JOURNAL



## Over 100 Clinical Trials Focused on:

- MDMA
- Psilocybin = Magic Mushrooms
- LSD
- Ketamine
- Ibogaine
- Depression
- Anxiety
- PTSD
- Substance Abuse

may someday bring relief from addiction, anxiety, depression – and even the fear of death."

And its not just the press either.

Academia is also fully on board.

Top researchers at Yale University, Johns Hopkins, Stanford, and many other top universities worldwide are paving the way forward for an entirely new class of drugs that can change the way we live, how well we live – and how long we live.

Importantly, as you will see below, there are literally hundreds of billions of dollars to be made as treatments are derived from this new class of drugs.

And opportunities are still available for savvy investors to get in early – and reap major rewards.

But first things first.

First, we need to talk about how psychedelics are quickly moving beyond mushrooms and club drugs, and taking a seat – at the head of the table – among legitimate prescription pharmaceuticals...

*"Psychedelics could tap into a large population of patients starved for new treatments. And for companies ready to jump on this colorful new bandwagon, the payout is expected to be huge."*

pharma  
MANUFACTURING

Because, frankly, that's where the money is.

So, here are a few great examples you won't see featured too many other places.



# Healthcare Heavyweight Makes Major Medicinal Psychedelics Discovery

Just ask healthcare giant **Johnson & Johnson (JNJ)** about the potential of medicinal psychedelics.

Today J&J generates more than half its \$82 billion in annual revenue from prescription pharmaceuticals...

And one of its latest success stories has helped spark a new wave in pharmaceutical research – and at its crest are psychedelics.

One of J&J's most recently approved pharmaceuticals is called Sprovata.

Sprovata is a nasal spray version of a prescription form of the drug eskatamine.

Esketamine was first used in Germany in the 1990s as an anesthetic drug.

Esketamine is what's called an enantiomer (like a molecular mirror image) of ketamine -- and is part of the psychedelic category of drugs with both medicinal and recreational applications.

And ketamine has long been a popular recreational drug.

For example, Vice News calls it "The Best Drug On Earth" for its use as a "horse tranquilizer, club drug, and cure for refractory depression."

But, forget about the horses and clubs...

Because it's the last part – about a treatment for depression – that is the real key to all this.

J&J's development of Sprovata is basically taking a version of a common recreational drug and turning it into a legitimate medicinal mental health treatment.

It is one of the latest approvals of a

prescription form of a psychedelic drug as an antidepressant and marks another step forward for the medicinal psychedelics industry.

But J&J and Sprovata aren't alone. They're part of a much larger rise of medicinal psychedelics – that are, quite literally, rich with potential profits.

Another example is in the critical – and elusive -- area of Post Traumatic Stress Disorder (PTSD) treatment.

As you may know, PTSD is one of the world's most vexing mental health conditions.

NPR sums it up best in its headline: **"To Treat PTSD, Veterans Have A Vast Array of Ineffective Solutions."**

PTSD is tough...

And that's what makes it a major opportunity for medicinal psychedelics -- specifically, methylenedioxymethamphetamine

I know that's a mouthful. So, let's just call it by its better-known trade name: MDMA.

MDMA is one of the most popular party drugs in the world.

But don't sell it short – because combined with psychotherapy, MDMA also may be one of the most effective possible treatments for PTSD, according to the

Multidisciplinary Association For Psychedelic Studies.

In fact, MDMA recently completed a Phase 2 trial for treating PTSD and is headed to Phase 3.

As a result, medicinal MDMA could be approved for treatment of PTSD as early as 2021...

Which has gained the rapt

attention of highly knowledgeable early investors.

But, that's just the beginning.

There are many more studies underway for medicinal forms of psychedelics including:

- Psilocybin
- LSD
- DMT
- Peyote
- Bufotenin

All of these psychedelics are being researched by the big pharmaceuticals in their exclusive, elusive hideaway labs as potential treatments for all the major healthcare depression, PTSD, anxiety, and more.

---

***"Parts of the brain that normally drive depression got switched off by [common psychedelic] psilocybin."***

**Science Focus**  
THE HOME OF BBC SCIENCE FOCUS MAGAZINE

---

That is because altogether these mental health conditions cost the healthcare system more than **\$300 BILLION** a year to treat...

And that, right there, is the key for au fait investors.

The combination of proven and potential effective treatments plus a huge market for developed and approved treatments give medicinal psychedelic investments massive potential.

Which is why some of the world's biggest and best investors are driving the development of medicinal psychedelics.

# Facebook's First Investor Bets Big On Psychedelics

that includes Peter Thiel.

Peter Thiel is quickly becoming one of the world's most successful investors.

In addition to being the first investor in Facebook (buying a 10% stake in the \$650 billion social media giant for just \$500,000), he has a string of early stage investments that have gone on to become huge successes.

Thiel was an early investor in AirBnB, LinkedIn, Spotify, Yelp, Stripe, and dozens of other multi-billion dollar tech companies. He was also an early investor in the cannabis global leader Tilray -- and was there for the **1000%** move it made in 2018.

Now he has invested early in psychedelics.

Specifically, Thiel has invested in a company called COMPASS Pathways.

COMPASS raised **\$80 million** in 2020 and is set to go public, we expect, later this year.

If the company does half as well as Tilray did out of the gate, the psychedelic sector is going to soar...

And investors moving in now will be sitting on monster gains.

In fact, it's already starting to build up in a big way and its creating an investment opportunity on the scale of cannabis back in 2016.

## Psychedelics In 2020 Is Like Buying Cannabis In 2016

The truth is, psychedelics has all the potential of the cannabis boom, and more.

And those who move in early stand to make fortunes.

How can we be so confident?

Well, let me take you back to 2015.

The legal cannabis market was in its infancy.

Only two states -- Colorado and Washington -- had legalized cannabis for recreational use.

But, unbeknown to most investors, the industry was building steadily and expanding by hundreds

of millions of dollars per year.

Then in 2016 when California legalized it during the election and Canada announced it was in the process of completely legalizing it, early-in investors caught a whiff of the action -- and the industry went gangbusters.

Billions of dollars of investment in infrastructure, farms, and research soon took the industry mainstream.

And there were tens of thousands of early investors who became overnight "Marijuana Millionaires."

We all remember when companies like Canopy Growth, Aurora

### Top Investors Lining Up For Psychedelics



**Peter Thiel**

Renowned Venture Capitalist

First investor in Facebook and early investor in Uber, AirBNB, and many others. His fund committed major investment when COMPASS Pathways raised \$80 million to fund clinical research in medicinal benefits of psychedelics.



**Kevin O'leary**

Shark Tank Star

Founded and sold software provider The Learning Company for \$4 billion now is a lead investor in psychedelic company MindMed.



**Bruce Linton**

Founder and Former CEO of Canopy Growth

After building and leaving the largest legal cannabis company in the world, he has invested in MindMed.



**Tim Ferriss**

NYT Bestseller and Top Podcaster

Early investor Uber, FB, Twitter, Alibaba, Shopify is now directly funding research in psychedelics as a alternative treatment for depression.

*"We can no longer ignore the potential of psychedelic drugs to treat depression."*

**The Guardian**

Cannabis, Aphria were all tiny “penny stocks.”

And in just two years, they were all worth \$10 billion or more. Will history repeat itself with psychedelics?

Well, some of the world’s savviest and most successful investors are betting it could happen all over again. And should that be the case, you could easily have another **Tilray (TLRY)** success story.

Tilray was the hottest cannabis stock in the world after it went public in July 2018 at just \$30 a share.

And by September -- just two months after going public -- Tilray shares hit **\$300 each**.

A 10-fold gain in a matter of weeks.

Tilray, you’ll recall, was one of the early-stage investments of Peter Thiel, too.

**And, now the same is set to happen all over again in psychedelics.**

Let me explain...



# Psychedelics Are Already Turning Small Investments Into Life-Changing Fortunes – For Those Savvy Enough to Get in Early



For savvy investors, the time to move is now -- because there is a major event coming that will propel these innovative treatments into the mainstream of financial markets.

The truth is, some select investors are walking away with fortunes...

But the biggest part of the run is still likely to come.

Just look at **Champignon Brands (CAN:SHRM / US:SHRMF)**.

This company has quickly emerged as an early leader in the psychedelics race...

And its shares are already up **1233%** in the past 10 weeks.

But that’s just one of the emerging psychedelic mushroom companies that are set to expode.

Another is **Newleaf Brands (CAN:NLB / US:NLBIF)**.

This is a cannabis company with

its own psychedelic mushroom division...

And its shares have soared **2025%** -- in just two months.

**New Wave Holdings (CAN:SPOR / US:TRMND)** is another psychedelic mushroom company set to take center stage...

And it has surged a staggering **2325%** -- in just three weeks. Even **MindMed (CAN:MMED / US:MMEDF)**, a relative “laggard” in the sector, is up **179%** from when it started trading in March. (That’s right, barely three months ago!)

I know you will agree, those gains are staggering... But, again, this is just the starting line.

And it’s not too late for you to still get in on the early action...

Because the next major catalyst is set for later this year.

# How To Win Big In Psychedelic Stocks

You've read the facts and seen the figures...

So, now you know for yourself that psychedelics are forming the basis for a medicinal revolution in the treatment of the complex and costly mental health conditions plaguing the world.

Johnson & Johnson has already developed an FDA-approved psychedelic for the treatment with recently approved Spravato.

MDMA is making it through the clinical proving stages on its way to becoming quite possibly the signal treatment for PTSD.

There are going to be additional developments unfolding daily as the top healthcare companies and top universities continuing research and developing more applications.

And that is precisely what the world's biggest – and best -- early stage investors are betting on it.

In the months and years ahead, there are going to be many major events that bring attention, legitimacy, credibility, and esteem to medicinal psychedelics.

And the investors who bet on the most highly prospective companies -- when they are in the early development stages -- stand to earn major windfall profits, time and time again.

Perhaps, including you.

So, stay tuned to *Psychedelic Stockwatch* to learn firsthand what those companies are...

And when to make your move for major profits.

Plus, there are some huge winners still to come in 2020 -- and we'll show you what they are and when to get in on the early action.

So, don't miss out – *on cashing in!*

## The Time To Invest In Psychedelics Is NOW

There are still many more developments to come for psychedelics in the future.

But, no event will probably more important than events surrounding COMPASS Pathways.

*“Psychedelics are the next big thing.”*

- Ronan Levy, co-founder of Field Trip Psychedelics



As I mentioned above, it is already one of the most-watched start-up psychedelic treatment developers in the world.

It has earned the almost impossible to get “Breakthrough Therapy” designation from the FDA.

It raised \$80 million in April -- and attracted investments from Peter Thiel and other world-class investors.

And the good news for you is that we expect Atai -- COMPASS Pathways's parent company -- to go public later this year.

When it does, we fully expect that it will be a monster IPO.

And if it gets the kind of attention Tilray did (which we expect it to do), the psychedelic stock sector is going to go on another tear.

Why?

Because this is the catalyst that will put the psychedelics sector on the proverbial map of the major investors around the world.

Which means that investors getting in now -- before this catalyst event occurs -- stand to make a veritable fortune.

**And here's how you can get in on it all...**



## Quick Start Guide:

# 3 Actions To Take NOW To Ensure You Ride The Psychedelics Boom All The Way To The Top

By completing this report, you have given yourself a major edge in making the most of the coming surge in psychedelics investments.

It's a good first step, but it's just a first step.

There are a few other quick and easy things you can do to make sure you're ready for the next leg of this.

And you'll want to do them now before they really get into full swing.

Here they are:

### 1. Put **PsychedelicStockWatch.com** in your “Favorites” tab.

Psychedelic Stock Watch is the first and only dedicated web portal offering independent research, medical research updates, and investment coverage all in one place.

### 2. Take Out Your Phone and Text “StockWatch” to 1-205-898-2241

This is a currently a free service to Psychedelic Stock Watch readers which will alert you to IPO's, psychedelic stock breakouts, and other essential psychedelic information and recommendations.

This SMS text alert service is currently free to sign up for, but we can't guarantee it will stay that way forever.

So please sign up now and make sure you get the most timely psychedelics investment information at no charge.

### 3. Check your e-mail Inbox again for an email from Psychedelic Stock Watch.

Included in there is some BONUS research that focuses exclusively on the investing side of psychedelics and some historical research on how to separate the future big winners from the pretenders today. Add [news@update.psychedelicstockwatch.com](mailto:news@update.psychedelicstockwatch.com) to your email whitelist. See [howtowhitelist.com](http://howtowhitelist.com) for instructions.

Psychedelic Stock Watch was created to guide individual investors through the psychedelics boom.

This report is the start and these specific actions will make sure you do take full advantage of the exceptional opportunity in psychedelics.

You're already ahead of the game.

Now stay ahead.

All the best,

**Psychedelic Stock Watch Team**